Funding Received
$82.1 Million in 4 Rounds from 8 Investors
Most Recent Funding
$25 Million Series C on May 6, 2014
Headquarters:
Evanston, IL
Description:
Naurex is a clinical-stage company developing novel therapeutics for depression and other CNS disorders.
Founders:
Joseph Moskal
Categories:
Biotechnology
Website:
http://www.naurex.com

Company Details

Update

Naurex Inc. is a clinical-stage company developing novel therapies for depression and other CNS disorders based on a new mechanism of action for modulating the N-methyl-D-aspartic acid receptor (NMDAR). Using these discoveries, Naurex researchers have generated novel chemical drug classes known as glycine-site functional partial agonists (GFPAs), which modulate the receptor in a different way than existing NMDAR agents. The company’s drug development programs based on its GFPA NMDAR modulators include the first-generation molecule, GLYX-13, the second-generation NRX-1050 small molecule series and additional compounds from Naurex’s platform of novel NMDAR modulators.

Investors (8)

Update

Offices/Locations (1)

Update
  • Office

    1801 Maple Avenue

    Suite 4300

    Evanston, IL 60201

    USA

Images (2)

Update
  • Fmqmlwuvjgsmzoofc0nc
  • 89c58801a5a21d0479f7d685eeb4518f